Pharmacological Inhibition of Lactation After 16 to 20 Week Abortion

• Status: Recruiting
• Trial end date: 2024-06-30
• Target enrollment: 0
• Participant gender: Female

Summary

The goal of this clinical trial is to compare breast symptoms (lactation, engorgement, etc) of individuals who undergo a procedure for second trimester of pregnancy loss between 16 weeks and 20 weeks gestational age. The participants will be randomly placed in two groups, one with a placebo tablet and one with medication called "cabergoline" which are taken immediately after their procedure. Researchers will compare groups to see if there are any significant differences in breast symptoms.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Northwestern University
• Treatments: Cabergoline

Criteria

Inclusion Criteria:

• pregnant individuals seeking termination of pregnancy after 16w0d gestation and up to 19w6d gestation. this includes management of intrauterine demises

• ages 18 to 50

• con provide informed consent in English

Exclusion Criteria:

• Age under 18 or above 50

• gestational ages before 16 weeks 0 days or after 20 weeks 0 days

• unable to provide written consent in English

• hypertensive disorder

• uncontrolled hypertension or known hypersensitivity to ergot derivatives

• History of cardiac valvular disorders

• history of pulmonary fibrosis

• documented bipolar schizophrenia

• documented allergy to medication, including lactose intolerance (placebo pill involves lactose)